Michael Burry Shutters Scion Asset Management, Renews AI Bubble Warning With Lord of the Rings Meme (International Business ...

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

The average one-year price target for Travere Therapeutics (NasdaqGM:TVTX) has been revised to $42.33 / share. This is an ...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, ...

Finerenone shows significant benefits in patients with kidney disease and type 1 diabetes, which could lead to the first ...

Sparsentan therapy was associated with sustained decline in proteinuria and lower likelihood of progression to kidney failure vs. irbesartan for pediatric patients with focal segmental ...

October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing autoimmune conditions.

The benefits are observed across patient subtypes and potentially offer the chance to avoid dialysis and implement a new standard of care.

Re-Time Pty Ltd (RTPL) today announced the launch of the retimer Ring, the first smart ring solution developed by an Australian company to help people improve sleep and overall wellbeing. Building on ...

Abortion in America, a growing national effort co-founded in 2024 by the late Cecile Richards, Kaitlyn Joshua, and Lauren ...

Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to $235 million (previously $200 million to $225 million) and core adjusted ...

It's been a pretty great week for Travere Therapeutics, Inc. ( NASDAQ:TVTX ) shareholders, with its shares surging ...